Rowena Henderson
University of Leeds(GB)Cancer Research UK Clinical Trials Unit(GB)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Cancer Treatment and Pharmacology, Protein Degradation and Inhibitors, Histone Deacetylase Inhibitors Research, DNA and Nucleic Acid Chemistry
Most-Cited Works
- → Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk(2022)80 cited
- → Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial(2016)76 cited
- → F railty-adjusted therapy i n T ransplant N on- E ligible patient s with newly diagno s ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial(2022)33 cited
- → Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial(2022)24 cited
- → Fitness, a UK Myeloma Research Alliance (UK-MRA) Frailty-Adjusted Therapy Study, Supports the Feasibility of Recruiting Frail Newly Diagnosed Myeloma Patients to Large Clinical Trials(2021)13 cited
- → Minimal Residual Disease in the Maintenance Setting in Myeloma: Prognostic Significance and Impact of Lenalidomide(2017)13 cited
- → Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma (FiTNEss): A UK Myeloma Research Alliance Study, Myeloma XIV(2019)13 cited
- → Ribonucleic acid in plasma from normal adults and multiple myeloma patients.(1979)8 cited
- → Frailty-adjusted therapy in transplant non-eligible patients with newly diagnosed multiple myeloma(2021)1 cited
- → A randomised phase II trial of selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma (RRMM) patients(2018)